Literature DB >> 20724532

The association of dipyridamole side effects with hemodynamic parameters, ECG findings, and scintigraphy outcomes.

Hamid Javadi1, Malihnaz Shariati, Mehdi Mogharrabi, Isa Neshandar Asli, Sara Jallalat, Aref Hooman, Mohammad Seyedabadi, Majid Assadi.   

Abstract

UNLABELLED: Dipyridamole has extensively been administered as a substitute for physical activity in cardiovascular assessment. The aim of this study was to evaluate the association of dipyridamole side effects with hemodynamic oscillations, scanning results, and electrocardiography (ECG) findings.
METHODS: Overall, 590 patients referred to the nuclear medicine center for myocardial perfusion imaging were evaluated for adverse dipyridamole effects concurrent with a low level of exercise. Before and during dipyridamole infusion, the patients' vital signs, electrocardiogram, heart rate, systolic blood pressure, and diastolic blood pressure were monitored; all patients underwent stress-rest (99m)Tc-sestamibi gated SPECT using a 2-d protocol.
RESULTS: Eighty-eight patients (14.9%) experienced at least one side effect during dipyridamole infusion, and abnormal ECG and scan results were observed in 32.4% and 48.6% of patients, respectively. We observed a positive correlation between a higher incidence of chest discomfort, headache, and dyspnea and abnormalities on ECG and myocardial perfusion imaging. In addition, these 3 side effects were also associated with a higher postinfusion heart rate, lower preinfusion systolic blood pressure, and lower postinfusion diastolic blood pressure. There were significant differences between pre- and postinfusion heart rate, preinfusion systolic blood pressure, and postinfusion diastolic blood pressure among patients with or without side effects, whereas no significant difference was observed in any of the hemodynamic parameters between patients with normal and abnormal ECG results or myocardial perfusion imaging results.
CONCLUSION: This study demonstrated a correlation between hemodynamic variables and side effects but not with imaging findings or ECG findings.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20724532     DOI: 10.2967/jnmt.109.072629

Source DB:  PubMed          Journal:  J Nucl Med Technol        ISSN: 0091-4916


  6 in total

1.  Relationship between gated myocardial perfusion SPECT findings and hemodynamic, electrocardiographic, and heart rate changes after Dipyridamole infusion.

Authors:  Arash Gholoobi; Narjess Ayati; Alireza Baghyari; Mohsen Mouhebati; Baharak Atar; Vahid Reza Dabbagh Kakhki
Journal:  Int J Cardiovasc Imaging       Date:  2017-02-01       Impact factor: 2.357

Review 2.  Pharmacological stress cardiovascular magnetic resonance.

Authors:  Runyawan Chotenimitkhun; W Gregory Hundley
Journal:  Postgrad Med       Date:  2011-05       Impact factor: 3.840

Review 3.  Identification of left ventricular myocardial ischemia and cardiac prognosis with cardiovascular magnetic resonance: updates from 2008 to 2010.

Authors:  Runyawan Chotenimitkhun; W Gregory Hundley
Journal:  Curr Cardiol Rep       Date:  2011-02       Impact factor: 2.931

4.  Effect of Dipyridamole Injected for Myocardial Perfusion Imaging on Blood Glucose Concentration; A Preliminary Study.

Authors:  Amirreza Khorasanchi; Mohsen Arabi; Alireza Akhavein; Mohammad Seyedabadi; Mansooreh Eftekhari; Hamid Javadi; Iraj Nabipour; Majid Assadi
Journal:  J Clin Diagn Res       Date:  2016-08-01

5.  Dipyridamole-induced adverse effects in myocardial perfusion scans: Dynamic evaluation.

Authors:  Sin-Di Lee; Wei-Chun Huang; Nan-Jing Peng; Chin Hu
Journal:  Int J Cardiol Heart Vasc       Date:  2016-11-27

6.  New concept of myocardial longitudinal strain reserve assessed by a dipyridamole infusion using 2D-strain echocardiography: the impact of diabetes and age, and the prognostic value.

Authors:  Thomas Cognet; Paul-Louis Vervueren; Laurent Dercle; Delphine Bastié; Rainui Richaud; Matthieu Berry; Pauline Marchal; Matthieu Gautier; Audrey Fouilloux; Michel Galinier; Didier Carrié; Pierre Massabuau; Isabelle Berry; Olivier Lairez
Journal:  Cardiovasc Diabetol       Date:  2013-06-07       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.